Articles

WHICH DRUGS ARE COMMONLY USED TO TREAT RA?

Click the link above to go to our section on the drugs that are commonly used in the treatment of rheumatoid arthritis, including DMARDs, biologics, steroids and painkillers.

Treatment strategies in patients with RA for whom methotrexate alone has failed

By NRAS
Taken from: NRAS magazine, Winter 2011

The risk of joint infections in those on anti-TNF therapies

By NRAS
Taken from: NRAS magazine, Winter 2011

The efficiency of abatacept and tocilizumab in patients with rheumatoid arthritis

By NRAS
Taken from: NRAS magazine, Winter 2011

The SWEFOT Trial

By NRAS
Taken from: NRAS magazine, Winter 2011

Golimumab (Simponi) is accepted for restricted use within NHS Scotland

By NRAS
Taken from: NRAS magazine, Winter 2011

NICE provisionally agrees the wider use of tocilizumab (RoActemra)

By NRAS
Taken from: NRAS magazine, Winter 2011

Hydroxychloroquine could reduce the risks of RA patients developing diabetes

By NRAS
Taken from: NRAS magazine, Autumn 2011

Head-to-Head trial scheduled for Cimzia and Humira

By NRAS
Taken from: NRAS magazine, Autumn 2011

EULAR: Expanding Research in Intracellular Signalling

By NRAS
Taken from: NRAS magazine, Autumn 2011

NICE update on Simponi (golimumab)

By NRAS
Taken from: NRAS magazine, Autumn 2011

NICE update on Orencia (abatacept)

By NRAS
Taken from: NRAS magazine, Autumn 2011

Comprehensive review of certolizumab pegol

By NRAS
Taken from: NRAS magazine, Winter 2010

Impact of abatacept (Orencia) on quality of sleep

By NRAS
Taken from: NRAS magazine, Winter 2010

JIA indication and extension of dose range for Metoject

By NRAS
Taken from: NRAS magazine, Winter 2010

Tasocitinib efficacy at different dosages

By NRAS
Taken from: NRAS magazine, Autumn 2010

Cimzia linked to improvements in productivity

By NRAS
Taken from: NRAS magazine, Autumn 2010

Do anti-TNF treatments change the cardiovascular risk of people with RA?

By NRAS
Taken from: NRAS magazine, Autumn 2010

TRACE RA Trial

By NRAS
Taken from: NRAS magazine, Spring 2010

Does methotrexate have an effect on cardiovascular disease in RA?

By NRAS
Taken from: NRAS magazine, Spring 2010

Cimzia (certolizumab pegol) approved by NICE

By NRAS
Taken from: NRAS magazine, Spring 2010

Ocrelizumab RA programme suspended

By NRAS
Taken from: NRAS magazine, Spring 2010

Influenza after rituximab

By NRAS
Taken from: NRAS magazine, Spring 2010

Window of opportunity to treat RA

By NRAS
Taken from: NRAS magazine, Spring 2010

Methotrexate and anti- TNF treatments less effective in people who smoke

By NRAS
Taken from: NRAS magazine, New Year 2010

People on Enbrel stay in work longer

By NRAS
Taken from: NRAS magazine, New Year 2010

RoActemra (tocilizumab) can inhibit joint damage when given with methotrexate

By NRAS
Taken from: NRAS magazine, New Year 2010

Encouraging early results with dnaJP1

By NRAS
Taken from: NRAS magazine, New Year 2010

Anti-TNF treatment does not increase cancer risk in people with RA

By NRAS
Taken from: NRAS magazine, New Year 2010

First UK home infusion of Remicade (infliximab) for RA

By NRAS
Taken from: NRAS magazine, Winter 2009

New innovative delivery system for Enbrel (etanercept)

By NRAS
Taken from: NRAS magazine, Winter 2009

Arzerra (ofatumumab) in RA

By NRAS
Taken from: NRAS magazine, Winter 2009

Development of Lodotra

By NRAS
Taken from: NRAS magazine, Winter 2009

New Metoject range

By NRAS
Taken from: NRAS magazine, Winter 2009

Simponi (golimumab) for people with RA who had a poor response to other anti-TNF treatments

By NRAS
Taken from: NRAS magazine, Winter 2009

RoActemra (tocilizumab), a novel biologic treatment launched for RA

By NRAS
Taken from: NRAS magazine, Winter 2009

Fostamatinib disodium fails in RA

By NRAS
Taken from: NRAS magazine, Winter 2009

Orencia effective in very early stage RA

By NRAS
Taken from: NRAS magazine, Spring 2009

RoActemra (tocilizumab) gains license in Europe for RA

By NRAS
Taken from: NRAS magazine, Spring 2009

Pamapimod fails in RA study

By NRAS
Taken from: NRAS magazine, Spring 2009

Metoject (MTX) available in a higher strengh thanks to feedback from patients

By NRAS
Taken from: NRAS magazine, Spring 2009

Pilot study shows 90% remission in early RA

By NRAS
Taken from: NRAS magazine, Winter 2008

Tocilizumab shown to inhibit progression of joint destruction & improves physical function of patients with RA

By NRAS
Taken from: NRAS magazine, Winter 2008

New Drug LT-NS001 in clinical trial

By NRAS
Taken from: NRAS magazine, Winter 2008

New Cimzia study shows rapid reduction of symptoms & inhibition of joint damage progression in RA

By NRAS
Taken from: NRAS magazine, Winter 2008

Methotrexate - Optimal dosage & route of administration

By NRAS
Taken from: NRAS magazine, Winter 2008

Enbrel (etanercept) has efficacy & safety data up to a decade of continuous use

By NRAS
Taken from: NRAS magazine, Winter 2008

New Study shows Humira (Adalimumab) can help children with juvenile idiopathic arthritis (JIA)

By NRAS
Taken from: NRAS magazine, Winter 2008

Co-proxamol Supplies

By NRAS
Taken from: NRAS magazine, Autumn 2007 & Winter 2008

News from EULAR 2008, the Annual European Congress of Rheumatology

By NRAS
Taken from: NRAS magazine, Autumn 2008

Early use of Enbrel (etanercept) in RA boosts quality of life & cuts absenteeism

By NRAS
Taken from: NRAS magazine, Autumn 2008

Methotrexate injections delivered to your door

By NRAS
Taken from: NRAS magazine, Winter 2007

Methotrexate survey of NRAS members

By NRAS
Taken from: NRAS magazine, Autumn 2007

ARCHIVE